Contact lenses to provide controlled drug delivery for Glaucoma

11th December 2013
LaserVision

Achieving controlled drug delivery from a contact lens has been a significant challenge in the field of ophthalmology for decades, but researchers from Harvard Medical School and the Massachusetts Eye and Ear department are now a step closer in achieving this.

Designed for the prolonged delivery of Latanoprost, the common drug for the treatment of Glaucoma, the contact lenses are designed to give consistent and sustainable doses of the drug and have been made with FDA-approved materials.

Appearing safe in cell culture and animal studies, this is an encouraging development for the treatment of Glaucoma, the leading cause of irreversible blindness in the world, and will no doubt pave the way for similar treatments.

LaserVision will keep you up to date on more developments on this subject.

Related Information

As Seen On

LaserVision is recognised by the following leading UK private medical insurers

Request a ConsultationAttend an Event